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erkel cell carcinoma (MCC), an uncommon
and highly aggressive cutaneous malig-
nancy, usually occurs on the sun-
damaged skin of the elderly and is characterized by
coexpression of neuroendocrine markers and
CK20, a discriminant from other types of visceral
neuroendocrine neoplasias. Since the discovery of
Merkel cell polyomavirus (MCV), many researchers
have confirmed its presence in about 80% of
cutaneous MCCs.1 Although some cutaneous MCCs
were reported to be associated with squamous cell
carcinomas (SCCs), such combined cases accounted
for only aminor portion and the viral status appeared
to be different from pure MCC.1-4 Rarely, primary
MCCs occur on the female vulva,5 with or without
combined SCCs,6,7 the latter is often human
papillomavirus (HPV) related.
CASE REPORT
A 63-year-old woman had a vulvar tumor over the
right labium majus for 5 years, with recent enlarge-
ment and pain. The erosive exophytic tumor
measured 5 cm in its greatest dimension. No other
cutaneous lesions were found. The excision
specimen consisted of a nodular dermal tumor
measuring 3.6 3 2.5 3 1.3 cm in size with an
eroded surface and irregular tumor borders.
Microscopically, the tumor was biphasic and
composed of: (1) a moderately differentiated
malignant squamous cell component with keratin
pearl formation; and (2) a poorly differentiatedthe Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung
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ail: liangcherwei@gmail.com.basophilic malignancy consisting of cells in
sheetlike pattern with high nucleocytoplasmic
ratio, vesicular nuclei, and small to occasionally
prominent nucleoli. Comedo necrosis was common,
without peripheral palisading. There was an abrupt
transition from the squamous component to the blue
cell component (Fig 1). Immunohistochemically,
the basophilic tumor cells expressed an immuno-
profile of synaptophysin1/chromogranin1/CK1
(dotlike)/CK201/CD561/CK5/p63/p161 (Fig 2),
whereas the squamous part was synaptophysin/
chromogranin/CK1 (diffuse)/CK20/CD56/
CK51/p631/p161, consistent with a primary tumor
of combined SCC andMCC. Both parts were negative
to MCV large T-antigen (CM2B4) antibody
(sc-136172, Santa Cruz Biotechnology, Dallas, TX)
(dilution 1:50). P53 was overexpressed in both
components.
Genomic DNA from both components was
collected from paraffin blocks via manual microdis-
section for HPV and MCV detection by polymerase
chain reaction (PCR) and TP53 gene mutation by
direct sequencing. To increase the chance for MCVJAAD Case Reports 2015;1:196-9.
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Fig 2. CK20 and synaptophysin immunostains. Right
upper area with CK201 immunostaining is Merkel cell
carcinoma (MCC) and left lower area is squamous
cell carcinoma. (Hematoxylin-eosin stain; original
magnification: 3400.) Inset, Synaptophysin1 immuno-
staining in MCC area.
Fig 1. Combined squamous and Merkel cell carcinoma
lesion. Area of transition between squamous (lower) and
Merkel cell (upper) carcinoma. (Hematoxylin-eosin
stain; original magnification: 3200.) Inset, Human
papillomavirus E6/E7 messenger RNA expression in both
components by RNAscope ISH.
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MCV1 MCCs were included as the biologic positive
controls. No MCV DNA (Fig 3) or inactivating
mutation in the TP53 was detected. By contrast, an
identical clone of type-16 HPV in both components
was identified (Fig 3). To eliminate possible
cross-contamination, we validated the result by
RNAscope in situ hybridization to detect HPV
E6/E7 messenger RNA expression on slides and
identified cytoplasmic punctate dots in both
components (Fig 1).
DISCUSSION
MCC, known as a primary neuroendocrine
carcinoma of the skin, tends to affect the elderly
and is associated with chronic sun damage,
immunosuppression, or both. Feng et al9 first
demonstrated the clonal integration of MCV DNA
in the cutaneous MCC tumor cells. Later, several
studies indicated that no MCV DNA was detected in
other visceral high-grade neuroendocrine
carcinomas. These discoveries stressed the
oncogenic role of MCV in cutaneous MCCs.
However, there are insufficient data regarding the
role of MCV in MCCs arising from unusual
sun-protected regions of the body. In the current
case, a combined SCC component raises the
suspicion of HPV DNA integration, rather than
MCV DNA, as the pathogenesis of vulvar MCC
development. We have determined this by PCR
demonstrating the 2 malignant components
(squamous and neuroendocrine) incorporating the
same high-risk HPV DNA in their genome, but no
MCV DNA. Moreover, combined squamous
and neuroendocrine carcinomas of skin in
sun-damaged regions share ultraviolet lighterelated
TP53 mutations in both components,10 whereas inthe current case the TP53mutation is lacking, further
supporting the concept of MCV-independent and
HPV-related tumorigenesis in vulvar MCCs.
Busam et al1 reported 7 cutaneous SCC-MCC
combined lesions, immunonegative to CM2B4
antibody, which was against an antigenic epitope
on theMCV T antigen. Paik et al3 reported another 15
SCC-MCC combined lesions, which were all
immunonegative to CM2B4 antibody. Kuwamoto
et al2 reported 4 MCV cutaneous SCC-MCC
combined lesions, investigated by CM2B4 antibody
and real-time PCR. Later, Mitteldorf et al4 reported 2
patients with cutaneous SCC-MCC combined lesions,
and detected MCV DNA in both cases and HPV
type-6 DNA in one of them by PCR. It seems that by
current definition, MCCs are a heterogeneous group
of diseases that share similar morphological
and immunohistochemical features and are
related to miscellaneous conditions including MCV
infection, ultraviolet light damage, arsenic intoxica-
tion, immunosuppression, and on the vulva, HPV
infection.
Vulvar MCC is extremely rare with fewer than 20
cases reported in the English-language medical
literature.6,7 However, neuroendocrine carcinoma
of the uterine cervix is a well-established entity that
is highly correlated with HPV type-18 infection.11
Generally, 2 major pathogenetic routes are linked to
the development of vulvar carcinoma, ie, HPV
infection and inflammatory dermatoses. The result
from this study suggests that a portion of vulvar MCC
is HPV related (cervical type), whereas the other
portion is more akin to usual cutaneous MCV-related
MCC (cutaneous type). An association with basaloid-
type (or moderately to poorly differentiated) SCC
may argue for the former, whereas an association
Fig 3. Polymerase chain reaction. Set 7 primer8 showed no Merkel cell polyomavirus (MCV)
DNA detected in squamous cell carcinoma (SCC ) and MCC parts; human papillomavirus (HPV)
16 was detected in both SCC and MCC parts of the tumor (HPV gene chip revert blot
hybridization, primers MY09/GP61 and GP51/GP61).
Table I. Merkel cell carcinoma of the vulva
References Age, y Location Size, cm Combined SCC MCV test HPV test TP53 test
Tang et al,13 1982 67 Labium minus 1.5 SCC in situ ND ND ND
Bottles et al,14 1984 73 Labium majus 3 3 2 SCC in situ ND ND ND
Copeland et al,15 1985 59 Labium majus 8 3 6 Absent ND ND ND
Husseinzadeh et al,16 1988 47 Labium minus 4.2 3 3 Absent ND ND ND
Chandeying et al,17 1989 28 Labium majus 4 Absent ND ND ND
Cliby et al,18 1991 35 Vulva \1 Absent ND ND ND
Loret de Mola et al,19 1993 49 Fourchette 2 Absent ND ND ND
Chen,20 1994 68 Vulva 3 3 2.5 Absent ND ND ND
Scurry et al,21 1996 68 Labium minus 4 3 3 Squamous
differentiation
ND ND ND
Fawzi et al,22 1997 78 Vulva 5.5 Absent ND ND ND




Hierro et al,24 2000 79 Labium minus 2.5 Absent ND ND ND
Khoury-Collado et al,25 2005 49 Bartholin gland 2 Absent ND ND ND
Pawar et al,26 2005 35 Labium majus 6 3 4 Absent ND ND ND
Mohit et al,27 2009 50 Labium majus 12 3 10 Absent ND ND ND
Sheikh et al,6 2010 63 Labium majus 7 3 5 Absent ND ND ND
Iavazzo et al,7 2011 63 Vulva 9 Absent ND ND ND
Current case 63 Labium majus 3.6 3 2.5 Present Negative Positive Negative
HPV, Human papillomavirus; MCV, Merkel cell polyomavirus; ND, not done; SCC, squamous cell carcinoma.
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suggest the latter. Unfortunately, the reported
vulvar MCC cases in English-language literature
seldom included this information, and tests for
HPV and MCV were rarely done (Table I). The
current case suggests that a subset of vulvar MCC isHPV related. This also suggests that the phenotype
of MCC might represent a distinctive pathway of
HPV-related tumorigenesis in certain body
regions. Interestingly, Schrama et al12 recently
found the coexistence of MCV and HPV
DNA in mutation-specific BRAF inhibitor-induced
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that an epigenetic scenario of MCV ‘‘hit-and-run
tumorigenesis’’ might also be considered in the
current case.
Based on the experiences from cutaneous MCCs,
patients with combined SCC and MCC matched pure
MCC in clinical aggressiveness. They tended to
progress rapidly and have metastatic foci with pure
neuroendocrine features. As for the patients with
vulvar MCC, most of the patients died within the
first 2 years after diagnosis. Our patient died of
cancer-related cachexia and infection 6 months after
initial diagnosis. Chemotherapy and radiotherapy
provided only limited benefits. However, our case
implicates that prophylactic vaccination against
oncogenic HPV could prevent not only anogenital
SCC, but also certain cases of HPV-associated
vulvar/genital MCC. With efforts to elucidate the
pathogenesis of vulvar MCCs (eg, HPV, MCV,
ultraviolet related), further individualized therapy
could be expected.REFERENCES
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